Cilostazol had a favorable effect on lipid profiles and anti-atherosclerosis in obese subjects by reducing PCSK9 and enhancing LDLR expression, supporting its therapeutic application in such clinical settings. The gene discussed is PCSK9; the disease is atherosclerosis.